2025-10-09 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the data provided. I'll structure it in a way that mirrors your request, starting with the numbers and moving to analysis.

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company focused on developing and marketing innovative medicines and vaccines.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** 2.15%
*   **VOO Cumulative Return:** 99.62%
*   **Relative Divergence:**
    *   **Current:** -93.1
    *   **Max:** 23.9
    *   **Min:** -103.9
    *   **Relative Position:** 8.5

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO).  The relative divergence of -93.1 indicates a substantial performance gap. A relative position of 8.5 suggests that MRK's current underperformance is near its worst relative performance compared to VOO over the observed period.

**Alpha, Beta Analysis:**

| Year      | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| --------- | ------ | ------ | ------- | ------ | ------ |
| 2015-2017 | 1.0%   | 68.5%  | -28.0%  | 0.0    | 134.1  |
| 2016-2018 | 36.0%  | 69.8%  | 21.0%   | -0.0   | 182.1  |
| 2017-2019 | 40.0%  | 69.8%  | 18.0%   | 0.3    | 216.8  |
| 2018-2020 | 16.0%  | 79.6%  | -8.0%   | 0.3    | 195.0  |
| 2019-2021 | 2.0%   | 79.6%  | -44.0%  | 0.7    | 191.4  |
| 2020-2022 | 15.0%  | 79.6%  | 16.0%   | 0.7    | 277.1  |
| 2021-2023 | 33.0%  | 79.6%  | 31.0%   | 0.3    | 272.3  |
| 2022-2024 | -4.0%  | 79.6%  | -25.0%  | 0.2    | 248.5  |
| 2023-2025 | -47.0% | 71.5%  | -111.0% | 1.5    | 215.8  |

**Analysis:**

*   **CAGR:** Fluctuates significantly. The recent period (2023-2025) shows a substantial decline.
*   **MDD:** High Maximum Drawdown across all periods indicates significant price volatility and potential risk.
*   **Alpha:** Alpha is volatile, often negative, suggesting MRK frequently underperforms relative to its risk-adjusted expected return.  The recent period (2023-2025) shows a dramatically negative alpha.
*   **Beta:**  Beta is generally low, indicating MRK is less sensitive to market movements than the S&P 500. However, the Beta of 1.5 from 2023-2025 stands out.

### 2. Recent Price Action

*   **Current Price:** 86.40
*   **Last Market Data:** {'price': 86.4, 'previousClose': 87.61, 'change': -1.38}
*   **5-day Moving Average:** 88.30
*   **20-day Moving Average:** 83.30
*   **60-day Moving Average:** 82.99

**Analysis:**  The price closed at 86.40, which is down from the previous close of 87.61, indicating a slight recent decline. The 5-day moving average is above the 20-day and 60-day moving averages, suggesting a possible short-term upward trend, but the price is currently below the 5-day average.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 62.06 (Approaching Overbought)
*   **PPO:** 0.8794
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (35 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** 8.5 (Positive - Short-term Increase)
*   **Expected Return (%):** -67.9%

**Analysis:**

*   **MRI:** The MRI suggests a "High Investment Recommended" level of risk.
*   **RSI:** The RSI of 62.06 is approaching overbought territory, suggesting the stock may be due for a pullback.
*   **PPO:** The Positive PPO indicates that the shorter-term moving average is above the longer-term moving average, which may signal an upward trend.
*   **Hybrid Signal:**  The hybrid signal suggests a strong buy recommendation.
*   **Recent Relative Divergence Change:** The positive change indicates MRK is starting to close the performance gap with VOO, but it is still significantly behind.
*   **Expected Return:** The very negative expected return suggests significant underperformance relative to the S&P 500 over the long term (2+ years).

### 4. Recent News & Significant Events

*   **Verona Pharma plc (VRNA) Acquisition:**  This might indirectly affect the sector sentiment.
*   **Jefferies Adjusts Price Target on Merck:** A price target reduction from $141 to $137 suggests a slightly less optimistic outlook from Jefferies.
*   **Chart Expert Says Merck (MRK) Has More Upside:** Contrasts with the price target reduction and provides a bullish perspective based on chart analysis.
*   **Pfizer's Oncology Drugs:** Relevant as Pfizer is a major competitor in the pharmaceutical space.
*   **3 Large Drug Stocks to Watch:** Positions Merck within the broader industry context.

**Impact:** The news is mixed. The price target reduction is a negative, but the chart expert's positive outlook is a counterpoint. Sector news regarding Pfizer is relevant for competitive analysis.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean = 2.00)
*   **Opinions:** 25
*   **Target Price:**
    *   **Average:** 101.44
    *   **High:** 137.00
    *   **Low:** 82.00

**Analysis:**  The analyst consensus is "Buy" with an average price target of 101.44. This suggests analysts generally believe the stock is undervalued, despite recent underperformance. However, there is a wide range in target prices, indicating some uncertainty.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
| ---------- | ---- | --------- |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2024-08-05 | 2.15 | 16.11 B$  |
| 2025-08-05 | 2.15 | 16.11 B$  |

**Analysis:** EPS and Revenue have fluctuated. Most recent EPS is showing a slight decline, while revenue is relatively consistent, but not trending upwards.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| ---------- | -------- | ------------- |
| 2025-06-30 | $15.81B | 77.50%        |
| 2025-03-31 | $15.53B | 77.98%        |
| 2024-12-31 | $15.62B | 75.50%        |
| 2024-09-30 | $16.66B | 75.51%        |
| 2024-06-30 | $16.11B | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
| ---------- | -------- | ------- |
| 2025-06-30 | $48.99B | 9.04%   |
| 2025-03-31 | $48.34B | 10.51%  |
| 2024-12-31 | $46.31B | 8.08%   |
| 2024-09-30 | $44.50B | 7.09%   |
| 2024-06-30 | $43.58B | 12.52%  |

**Analysis:**

*   **Revenue:** Revenue is relatively stable, but not showing strong growth.
*   **Profit Margin:** Profit margins are very high, indicating strong cost control and pricing power.
*   **Equity:** Equity is trending upwards, showing growth in the company's net worth.
*   **ROE:** ROE is fluctuating, with the most recent quarter showing a decline.

### 7. 종합적인 Analysis (Overall Analysis)

**Summary:**

Merck (MRK) is a large pharmaceutical company with high profit margins and a generally positive analyst outlook. However, it has significantly underperformed the S&P 500 recently, and its expected return is negative.

**Key Observations:**

*   **Underperformance:** MRK has significantly underperformed the S&P 500.
*   **Financial Strength:** The company has strong financials, with high profit margins and growing equity.
*   **Analyst Sentiment:** Analysts generally have a "Buy" rating, suggesting potential upside.
*   **Technicals:** Technical indicators are mixed, with the RSI approaching overbought and moving averages suggesting a short-term upward trend.
*   **Recent News:** Recent news provides mixed signals, with a price target reduction offset by a chart expert's bullish view.
*   **Risk:** The high Maximum Drawdown across all periods indicates significant price volatility and potential risk.
*   **Recommendation**: Hybrid Signal is strong buy but the negative expected return을 반영해서 신중하게 투자할 필요가 있음

**Conclusion:**

MRK presents a mixed picture. While it has strong financials and analyst support, its recent underperformance, negative expected return, and potential volatility are significant concerns. Investors should carefully consider these factors before investing.
